Table 3. Patients who discontinued treatment with DTG+3TC.

Patient	Time to ART change (weeks)	Reason	Basal VL (c/mL)	w4	w12	w24	Final ART	Last VL (c/mL)
1	-	VFa	779	-	-	409	DTG/3TC	<50
2	1	M184Vb	1,875	<50	-	-	DRV/c/TAF/FTC	<50
3	2	CNS AE	142	-	-	-	RPV+TDF/FTC	<50
4	6	M184Vc	29,300	<50	-	-	DTG/RPV	<50
5	16	CNS AE	219	-	<50	-	DRV/c/TAF/FTC	LTFU
6	20	CNS AE	1,696	<50	<50	-	RPV/TAF/FTC	<50

ART: Antiretroviral treatment; VL: viral load; CNS AE: Central nervous system adverse event; VF: virological failure; LTFU: lost to follow-up.

^aVF according to physician’s criteria (only one VL ≥ 200 copies/mL but the patient stopped treatment).

^bThe participant had HIV-1 RNA 1,875 c/mL at baseline, switched to DRV/c/TAF/FTC on Day 8; <50 copies/mL on Day 59.

^cThe participant had HIV-1 RNA 29,300 c/mL at baseline, <50 copies/mL on Day 43, switched to DTG+DRV/c on Day 43; switched to DTG/RPV afterwards.